Ocugen (OCGN) Price & Analysis

Compare

6,298 Followers

OCGN Stock Chart & Stats

$1.91

-$0.04(-4.99%)

At close: Jan 08 4:00 PM EST

$1.91

-$0.04(-4.99%)

Day’s Range― - ―

52-Week Range$0.52 - $1.96

Previous CloseN/A

Volume1.89M

Average Volume (3M)3.84M

Market Cap

$587.16M

Enterprise ValueN/A

Total Cash (Recent Filing)$32.56M

Total Debt (Recent Filing)$32.96M

Price to Earnings (P/E)―

Beta1.56

Next Earnings

Mar 27, 2026

EPS Estimate

-0.06

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.07

Shares Outstanding312,320,100

10 Day Avg. Volume4,151,335

30 Day Avg. Volume3,836,074

Financial Highlights & Ratios

PEG Ratio0.17

Price to Book (P/B)7.36

Price to Sales (P/S)53.80

P/FCF Ratio-4.79

Enterprise Value/Market Cap0.00

Enterprise Value/Revenue0.00

Enterprise Value/Gross Profit0.00

Enterprise Value/Ebitda0.00

Forecast

1Y Price Target

$7.67

Price Target Upside301.57% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Addressable Market And Trial DataAnalysts highlight OCU410 in geographic atrophy targets an estimated one million patient market in the U.S., and full phase two data could significantly expand the company’s commercial opportunity.

Clinical Trial EnrollmentAnalysts note the pivotal OCU400 study in retinitis pigmentosa is nearing full enrollment, enabling submission of pivotal data to the FDA upon completion and potentially accelerating regulatory progress in 2026.

Partnerships And Early Commercial TractionAnalysts point to the licensing agreement with Kwangdong and higher-than-expected recent revenue as indicators of industry interest and early monetization that support ongoing development into 2026.

Bears Say

Ocugen News

Midday Fly By: TSMC reports Q4 beat, Goldman Sachs raises dividend

The major averages were broadly higher near noon, rebounding from back-to-back days of losses as optimism around a...

3h ago

Ocugen announces preliminary data from Phase 2 ArMaDa study

Ocugen (OCGN) announced preliminary 12-month data from the Phase 2 ArMaDa clinical trial evaluating OCU410, its novel modifier...

7h ago

OCGN

3 ‘Strong Buy’ Small Cap Stocks to Buy for 2026, According to Analysts

Analysts see strong upside potential in these three small-cap stocks. ...

1d ago

ALLO

BTBT

Ocugen announces publication of Phase 1 GARDian1 trial results for OCU410ST

Ocugen (OCGN) announced the publication of positive Phase 1 GARDian1 trial results for OCU410ST, its novel modifier gene...

3d ago

OCGN

Ocugen Reports Encouraging 12-Month Data for OCU410

Ocugen ( ($OCGN) ) has shared an update. On January 15, 2026, Ocugen reported positive preliminary 12‑month data...

6h ago

OCGN

Ocugen Grants CEO New Performance-Based Equity Award

Ocugen ( ($OCGN) ) has issued an update. In the fourth quarter of 2025, Ocugen’s Board, following a...

28d ago

OCGN

Ocugen’s Clinical Progress and Strategic Positioning Drive Buy Rating and Increased Price Target

Maxim Group analyst Michael Okunewitch has maintained their bullish stance on OCGN stock, giving a Buy rating today....

2M ago

OCGN

Ocugen’s Promising Gene Therapy Progress and Financial Stability Drive Buy Rating

Ocugen, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Swayampakula Ramakanth from H.C....

2M ago

OCGN

Ocugen Reports Progress in Gene Therapy Trials Amid Financial Losses

Ocugen Inc ( ($OCGN) ) has released its Q3 earnings. Here is a breakdown of the information Ocugen...

2M ago

OCGN

Ocugen Inc. Earnings Call: Gene Therapy Advances Amid Financial Challenges

Ocugen Inc (($OCGN)) has held its Q3 earnings call. Read on for the main highlights of the call....

2M ago

OCGN

OCGN Earnings this Week: How Will it Perform?

Ocugen Inc (OCGN) is scheduled to report 3rd quarter earnings on 11/05/2025, before the market opens. Regarding Q3...

2M ago

OCGN

Ocugen’s Promising Phase 2/3 Trial for Stargardt Disease: A Potential Game-Changer

Ocugen Inc (($OCGN)) announced an update on their ongoing clinical study. Study Overview: Ocugen Inc. is conducting a...

3M ago

OCGN

Ocugen’s Phase 3 Gene Therapy Trial: A Potential Game-Changer for Retinitis Pigmentosa

Ocugen Inc (($OCGN)) announced an update on their ongoing clinical study. Ocugen Inc. is currently conducting a Phase...

3M ago

OCGN

Ocugen initiated with a Buy at Lucid Capital

Lucid Capital analyst Elemer Piros initiated coverage of Ocugen (OCGN) with a Buy rating and $15 price target...

4M ago

OCGN

OCGN FAQ

What was Ocugen Inc’s price range in the past 12 months?

Ocugen Inc lowest stock price was $0.52 and its highest was $1.96 in the past 12 months.

What is Ocugen Inc’s market cap?

Ocugen Inc’s market cap is $587.16M.

When is Ocugen Inc’s upcoming earnings report date?

Ocugen Inc’s upcoming earnings report date is Mar 27, 2026 which is in 71 days.

How were Ocugen Inc’s earnings last quarter?

Ocugen Inc released its earnings results on Nov 05, 2025. The company reported -$0.07 earnings per share for the quarter, missing the consensus estimate of -$0.056 by -$0.014.

Is Ocugen Inc overvalued?

According to Wall Street analysts Ocugen Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Ocugen Inc pay dividends?

Ocugen Inc does not currently pay dividends.

What is Ocugen Inc’s EPS estimate?

Ocugen Inc’s EPS estimate is -0.06.

How many shares outstanding does Ocugen Inc have?

Ocugen Inc has 312,320,100 shares outstanding.

What happened to Ocugen Inc’s price movement after its last earnings report?

Ocugen Inc reported an EPS of -$0.07 in its last earnings report, missing expectations of -$0.056. Following the earnings report the stock price went down -1.399%.

Which hedge fund is a major shareholder of Ocugen Inc?

Currently, no hedge funds are holding shares in OCGN

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Ocugen Stock Smart Score

Neutral

Fundamentals

Return on Equity

-289.93%

Trailing 12-Months

Asset Growth

-7.01%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.

Ocugen (OCGN) Earnings & Revenues

Historic Earnings Reports

OCGN Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call highlighted significant advancements in gene therapy programs and strategic partnerships, alongside promising clinical data. However, the company faced increased operating expenses and a decline in cash position. Overall, the positive advancements and strategic positioning contribute to an optimistic outlook.View all OCGN earnings summaries

OCGN Stock 12 Month Forecast

Average Price Target

$7.67

▲(301.57% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","9":"$9","-1":"-$1","1.5":"$1.5","6.5":"$6.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$8.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$7.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$7.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,1.5,4,6.5,9],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.35,1.8615384615384616,2.3730769230769235,2.884615384615385,3.3961538461538465,3.907692307692308,4.41923076923077,4.930769230769231,5.442307692307693,5.953846153846154,6.465384615384616,6.976923076923077,7.488461538461539,{"y":8,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.35,1.8361538461538462,2.3223076923076924,2.808461538461539,3.2946153846153847,3.780769230769231,4.266923076923077,4.753076923076923,5.239230769230769,5.725384615384616,6.211538461538462,6.697692307692307,7.183846153846154,{"y":7.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.35,1.7846153846153847,2.2192307692307693,2.653846153846154,3.0884615384615386,3.5230769230769234,3.957692307692308,4.392307692307693,4.826923076923077,5.261538461538462,5.696153846153846,6.13076923076923,6.565384615384616,{"y":7,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.8,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.73,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.65,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.65,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.74,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.84,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.92,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.99,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.03,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.68,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.56,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.18,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.35,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >